Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

UK Gathers Global Leaders For Pandemic Preparedness Project

Task Force Also Being Set Up On New COVID-19 Antiviral Treatments

Executive Summary

New government funding to boost vaccine manufacturing and research into variant vaccines is being made available as part of the UK’s ambitious plans for a partnership to accelerate the availability of vaccines and other products for future pandemics.

You may also be interested in...



Coronavirus Notebook: 1.2bn Vaccines Produced Worldwide, ROVI To Double Moderna Capacity, Valneva starts UK Phase II/III trial

The World Health Organization has updated progress with evaluations of two Chinese vaccines and Russia's Sputnik V, the UK has ordered 60 million more Pfizer/BioNTech doses, and the European Medicines Agency is looking at the use of baricitinib in COVID-19 patients requiring oxygen.

WHO Chief Scientist Warns Of 'Pandemic Within A Pandemic', Calls For New R&D Models

A high profile panel including the WHO's chief scientist and ministers of Norway and South Africa discussed critical dimensions pertaining to coronavirus vaccines and risks of a “pandemic within a pandemic” with the emergence of  SARS-CoV-2 variants. Funding gaps at the ACT Accelerator and extending the shelf life of vaccines were also deliberated.

Coronavirus Notebook: UK To Speed Up Trials Of New Drugs, Expands Use Of Tocilizumab

AstraZeneca and BioNTech are both boosting production of their vaccines in Europe, and the first batches of Comirnaty have arrived in Australia and New Zealand.

Topics

Related Companies

UsernamePublicRestriction

Register

PS144188

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel